German Federal Court of Justice Upholds AOP's License Rights in Ropeginterferon and PEC's Liability for Damages.
Since 2017, PharmaEssentia had repeatedly attempted to terminate the agreement with AOP concerning BESREMi® (Ropeginterferon alfa-2b). In October 2020, after two and a half years of arbitral proceedings, the ICC Arbitral Tribunal issued its award in the matter